ArticleInfection and drug resistance2022
Analysis of Risk Factors and Mortality of Patients with Carbapenem-Resistant
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk factors for carbapenem-resistant Klebsiella pneumoniae infection in hospitalized patients: a meta-analysis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Prevalence of genes encoding carbapenem-resistance in Klebsiella pneumoniae recovered from clinical samples in Africa: systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Caerin 1.1/1.9 Inhibits Growth and Biofilm Formation of Carbapenem-Resistant Klebsiella pneumoniae and Induces Coordinated Transcriptomic Stress Responses.Current microbiology · 2026Article
- Clonal dissemination and plasmid plasticity of KPC-3-producing Klebsiella pneumoniae ST512 during a hospital outbreak in Spain.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Resistance, Virulence, and Molecular Epidemiology of Carbapenem-ResistantMicroorganisms · 2026Article
- Interpretable machine learning for early detection of carbapenem-resistantFrontiers in public health · 2026Article
- Survey-based risk factors and genomic characterization of oral and oropharyngealFrontiers in veterinary science · 2026Article
- Novel bacteriophages effectively target multidrug-resistant clinical isolates of Klebsiella pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- First identification of an ST11-KL64 hypervirulentFrontiers in microbiology · 2026Article
- Research article proteomics-based plasma biomarkers for predicting CRKP infection in ICU sepsis patients.Frontiers in pharmacology · 2026Article
- Carbapenem resistance in aAntimicrobial agents and chemotherapy · 2025Article
- Clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- Metagenomic profiling of pigeon faecal microbiota: insights into microbial diversity, pathogens, and antimicrobial resistance genes.Antonie van Leeuwenhoek · 2025Article
- "Global divide in carbapenem resistance and hypervirulence of Klebsiella pneumonia: comparing trends in India and developed nations"- a comprehensive review.The Journal of antibiotics · 2025Review
- Coexistence of blaScientific reports · 2025Article
- Dissemination ofMicrobiology spectrum · 2025Article
- Molecular characteristics and antimicrobial susceptibility of carbapenem-resistantFrontiers in microbiology · 2025Article
- Standardized pre-bronchoscopy mechanical power and KPC resistance as predictors of mortality in ventilated ICU patients: a retrospective cohort study.Frontiers in medicine · 2025Article
- Retrospective Case-Control Study of Risk Factors for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: The study retrospectively analyzed clinical characteristics and microbiological data from patients infected with KP from January 2019 to October 2021 to identify risk factors and mortality, using multivariate logistic regression analysis and Cox regression analysis. Results: A total of 214 KP inpatients were enrolled in our study. The in-hospital mortality rate was significantly higher in patients infected with CRKP (13/68, 19.12%) than carbapenem-susceptible KP (CSKP) (2/146, 1.37%) and the difference was statistically significant (P= 0.03). Multivariate Cox regression analysis showed CRKP isolation (HR 12.26, 95% CI 2.43-61.68, P = 0.002), lower TP (HR 10.50, 95% CI 1.33-82.76, P = 0.03), antibiotic days of therapy >15 (HR 0.08, 95% CI 0.01-0.56, P= 0.01) and length of stay (LOS) (HR 0.03, 95% CI 0.002-0.61, P= 0.02) were independent risk factors for death from KP. Additionally, intensive care unit (ICU) stay (OR 21.69, 95% CI 4.50-118.76, P< 0.001) and previous carbapenem exposure (OR 5.26, 95% CI 1.38-21.19, P= 0.02) are independent risk factors for CRKP. Conclusion: Our findings showed that patients infected with CRKP have a higher in-hospital mortality rate. Identifying the independent risk factors for CRKP infection may contribute to the management of CRKP and reduce the mortality of KP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.